Mast Therapeutics (MSTX +1.4%) gains today after the European Commission granted orphan-drug...

|About: Mast Therapeutics, Inc. (MSTX)|By:, SA News Editor

Mast Therapeutics (MSTX +1.4%) gains today after the European Commission granted orphan-drug designation to it's MST-188 drug candidate, a potential treatment for sickle cell disease. The decision gives MSTX 10 years of marketing exclusivity, and follows a similar positive opinion by the Committee for Orphan Medicinal Products. The company says it expects to now pursue strategic alliances "more aggressively."